Hui Qiu

This inventor holds 24 USPTO granted patents and 3 published patent applications, plus 7 CIPO patents and 9 EPO patents, primarily in Kinase Inhibitors. Top assignees: Merck Patent Gmbh, Paq Therapeutics Inc., Vertex Pharmaceuticals, Inc.. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hui Qiu. Retrieved from https://idiyas.com/inventor/hui-qiu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 3)

% Patents Active = 83.3

CIPO Patents = 7 (Patent Applications = 1)

EPO Patents = 9 (Patent Applications = 9)

Average Co-Inventor Count = 7.1

ph-index = 4

Forward Citations = 57(Granted Patents)

Location History:

Waltham, MA (US) (2014)
Lexington, MA (US) (2019)
Acton, MA (US) (2014 - 2024)

Company Filing History:

Paq Therapeutics Inc.

patents

2 out of 1,167

Vertex Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

KRAS Proteolysis

Brutons Tyrosine Kinase

GCN2 Inhibitors

Heteroaryl Compounds

Aminopyrimidine Derivatives

Pyrimidine Compounds

Pyridine Compounds

Glycosidase Inhibitors

Amino Azaheterocyclic Carboxamides

Imidazole Amines

Modulators of Kinase Activity

Pyrano Thiazole

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12599672 - KRAS proteolysis targeting chimeras (2026-04-14),

2. 12415803 - Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) (2025-09-16),

3. 12404285 - KRAS G12D proteolysis targeting chimeras (2025-09-02),

4. 12084438 - GCN2 inhibitors and uses thereof (2024-09-10),

5. 11098041 - Heteroaryl compounds as BTK inhibitors and uses thereof (2021-08-24),

6. 10793563 - GCN2 inhibitors and uses thereof (2020-10-06),

7. 10493073 - Heteroaryl compounds as BTK inhibitors and uses thereof (2019-12-03),

8. 10413562 - Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity (2019-09-17),

9. 10329270 - Heteroaryl compounds as BTK inhibitors and uses thereof (2019-06-25),

10. 10253023 - Heteroaryl compounds as BTK inhibitors and uses thereof (2019-04-09),

11. 10080750 - Aminopyrimidine derivatives for use as modulators of kinase activity (2018-09-25),

12. 10045985 - Heteroaryl compounds as BTK inhibitors and uses thereof (2018-08-14),

13. 10016448 - Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity (2018-07-10),

14. 10005784 - Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof (2018-06-26),

15. 9738648 - Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof (2017-08-22),

Title: Innovations and Contributions of Hui Qiu in Pharmaceutical Patents

Introduction

Hui Qiu is a prominent inventor based in Acton, MA, who has made significant contributions to the field of pharmaceuticals. With a remarkable total of 21 patents, his work showcases a strong dedication to the advancement of medical science and drug development.

Latest Patents

Among his latest innovations, Hui Qiu has developed patents related to GCN2 inhibitors and various heteroaryl compounds that function as BTK inhibitors. The GCN2 inhibitors patent presents compounds, compositions, and methods for using these compounds effectively. Additionally, his work on imidazo pyridine compounds offers pharmaceutical compositions that serve as useful BTK inhibitors, highlighting his innovative approach to combatting various medical conditions.

Career Highlights

Hui Qiu has been associated with notable companies such as Merck Patent GmbH and Vertex Pharmaceuticals, Inc. His experiences at these organizations have significantly contributed to his expertise in pharmaceutical patents and innovations.

Collaborations

Throughout his career, Hui Qiu has worked alongside skilled professionals, including coworkers Lesley Liu-Bujalski and Igor Mochalkin. Their collaborative efforts in the realm of patent applications have further enriched the body of knowledge in the industry.

Conclusion

Hui Qiu's impressive portfolio of patents and his collaborations with leading figures in the pharmaceutical sector underscore his vital role as an inventor. His work on GCN2 inhibitors and BTK inhibitors not only reflects his innovative spirit but also promises advancements that can enhance therapeutic options for patients worldwide.

Profile summary based on public USPTO records.